Articles in this Issue

• Resistance to Kinase Inhibitors: Mechanisms, Challenges and Opportunities

  Isabelle Dussault, Ph.D.
  Kinase inhibitors are important medicines for the treatment of several types of cancers that harbor dominant genetic lesions in specific kinases. Indeed, tumors with activating mutations, amplifications or translocations of kinases, often ... read more

• Flow Cytometry on Disaggregated Solid Tissues

  Vera S. Donnenberg, Ph.D., Albert D. Donnenberg, Ph.D.
  Flow cytometry represents a powerful tool for understanding the heterogeneity of tumors and their normal tissue counterparts. Along with the ability to interrogate millions of cells and characterize rare populations with respect to expression of... read more

• Next Generation Sequencing Roundtable

  Jeffery A. Schloss, Ph.D, Jessica Vamathevan, Ph.D., Gene Cutler, Ph.D., Andrew Barry
  1. How in your mind, has pharma thus far handled the challenge of increased NGS data mass as it applies to informatics and computing hardware? JS: The industry clearly has ability to work with large and sophisticated datasets – storage and ... read more

• Selective Integration of Label-free Technology Platforms to Enhance GPCR Drug Discovery Processes

  Liang Schweizer, Ph.D., Mary Ellen Cvijic, Ph.D., Litao Zhang, Ph.D.
  Label-free technologies are emerging technology platforms which have recently been introduced into the pharmaceutical industry for applications such as examining GPCR signaling. In this paper, we will discuss how label-free technology platforms ... read more

• Fragment-based Drug Discovery - From Hit Discovery to FDA Approval: Lessons Learned and Future...

  Terry V. Hughes, Ian Baldwin, Ian Churcher
  The last decade has seen a continued growth in the use of fragment-based drug discovery (FBDD) approaches in the identification and optimization of drug candidates. This has yielded a pipeline of FBDD-derived assets undergoing clinical ... read more

• Dealing with Positive In Vitro Mammalian Cell Genotoxicity Assays

  Timothy W. Robison, Ph.D.
  Registration of small molecule pharmaceuticals requires a comprehensive assessment of their genotoxic potential using a standard battery of tests. The genetic toxicity tests of the standard battery are in a period of re-evaluation to assess ... read more